|
Dear Friends and Colleagues,
Our work is more important now than ever. COVID-19 has wreaked havoc on our lives for more than a year, and the impact on brain health is clear. Research is showing that stress, depression, and suicide are on the rise, while the long-term impacts of COVID on the brain are unknown.
What we do know is that brain health matters—and it is essential for our wellness.
As we close out this year and look toward the next, let’s think about what we should collectively invest to ensure that we maintain and optimize brain health across our lifetimes. How do we advocate that governments prioritize the mental wellness of their citizens— putting Brain Health and Brain Capital at the top of their policy and funding agendas? How do we ensure that companies understand the critical role they play as well? The “great resignation” is a symptom of a system that failed to optimize work-life balance. Finally, how do we transform our healthcare model so that brain health is recognized as part of physical health?
Together, and individually, we can raise our voices to drive a future where preventive and treatment solutions are prioritized and accelerated through global collaboration.
As we enter the holidays, I hope you take time to rest, reflect, and re-energize.
In the new year, I invite you to join forces to advance brain health for all! Cohen Veterans Bioscience will be there to help lead the fight.
With best wishes,
 Magali Haas, MD, PhD
CEO & President
Cohen Veterans Bioscience
|
Metabolites offer significant promise as biomarkers for PTSD, but realizing their true potential is dependent on being able to measure them accurately and consistently from one patient to the next. Through RAPID-Dx, our flagship biomarker discovery initiative aimed at fast-tracking precision diagnostics and therapeutics for brain diseases, we identified the metabolite platforms with optimal performance based on the specific metabolites of interest for PTSD.
The Brain Trauma Blueprint is a framework that enables stakeholder groups across government, academia, foundations, and industry to advance precision diagnostics and treatments for TBI through a coordinated effort. Authored by leading experts in the TBI field, a series of papers published in the Journal of Neurotrauma lay the framework for a roadmap to advance the field. 
CVB partnered with the American Brain Coalition and several other leading brain health organizations to advocate for two bills that would lay the foundation for the creation of a Neuroscience Center of Excellence at the Food and Drug Administration (FDA).
